Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigation...
Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news

Castle Biosciences to acquire mental health testing co. AltheaDX in deal worth up to $140M
Castle's current portfolio consists of tests for skin cancers, uveal melanoma and Barrett ’s esophagus, the firm said. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 5, 2022 Category: American Health Authors: Chris Mathews Source Type: news

IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreements for Evaluation of Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma and Additional cMET-Driven Tumors
SOUTH SAN FRANCISCO, Calif., March 14, 2022 -- (Healthcare Sales & Marketing Network) -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted ther... Biopharmaceuticals, Oncology IDEAYA Biosciences, Pfizer, darovasertib, crizotinib (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 14, 2022 Category: Pharmaceuticals Source Type: news

Novel Drug, First Tx Approved for Rare Uveal Melanoma Novel Drug, First Tx Approved for Rare Uveal Melanoma
A novel drug, the first in its class, is also the first treatment approved for use in uveal melanoma, a rare cancer of the eye, after it was shown to improve overall survival.FDA Approvals (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - January 27, 2022 Category: Opthalmology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Kimmtrak (tebentafusp-tebn) for the Treatment of Unresectable or Metastatic Uveal Melanoma
Kimmtrak is the first and only FDA approved therapy for the treatment of unresectable or metastatic uveal melanoma (mUM) Kimmtrak is the first T cell receptor (TCR) therapeutic to receive regulatory approval Kimmtrak demonstrated statistically... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 26, 2022 Category: Drugs & Pharmacology Source Type: news

Is Ocular Melanoma Same as Uveal Melanoma?
Title: Is Ocular Melanoma Same as Uveal Melanoma?Category: Diseases and ConditionsCreated: 10/4/2021 12:00:00 AMLast Editorial Review: 10/4/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 4, 2021 Category: Cancer & Oncology Source Type: news

Survival Up With Tebentafusp in Metastatic Uveal Melanoma
Overall survival longer with tebentafusp for HLA*02:01 - positive patients with previously untreated metastatic uveal melanoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 23, 2021 Category: Cancer & Oncology Tags: Oncology, Ophthalmology, Pharmacy, Journal, Source Type: news

Doctors identify an eye cancer culprit
Researchers have identified a molecular mechanism that drives the progression of uveal melanoma, an often lethal eye cancer in adults. (Source: Yale Science and Health News)
Source: Yale Science and Health News - September 13, 2021 Category: Universities & Medical Training Source Type: news

Melanoma of the eye: Preclinical tests show path toward treatment
(University of Alabama at Birmingham) A preclinical study offers hope for treatment of uveal melanoma, a rare and deadly cancer of the eye. A small molecule inhibitor has been identified that dampens the potent drivers of this tumor. In mouse models, the inhibitor strongly limited primary disease in the eye and metastatic tumor dissemination to the liver, and animals survived longer, without overt side effects. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 14, 2021 Category: Cancer & Oncology Source Type: news

Small uveal melanomas 'not always harmless', ground breaking study finds
(University of Liverpool) A new article from Liverpool ocular researchers demonstrates that small uveal (intraocular) melanomas are not always harmless, as the current paradigm suggests. Instead, a reasonable proportion of them have molecular genetic alterations, which categorises them as highly metastatic tumours. The article recommends that they should not be observed but rather treated immediately, to improve patients' chances of survival. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 19, 2021 Category: Cancer & Oncology Source Type: news

Tebentafusp improves OS: A First in Metastatic Uveal Melanoma Tebentafusp improves OS: A First in Metastatic Uveal Melanoma
First-line tebentafusp significantly improved overall survival (OS) when compared with immunotherapy or chemotherapy in patients with metastatic uveal melanoma in a phase 3 trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 16, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Penn spinout Linnaeus Therapeutics gets key FDA designation
A South Jersey biopharmaceutical firm spun out of the University of Pennsylvania got a boost Thursday when the Food and Drug Administration granted orphan drug designation for the company's lead new drug candidate. Linnaeus Therapeutics of Haddonfield received the designation for LNS8801. The experimental treatment is for patients with metastatic uveal melanoma, a rare cancer that occurs within the eye. The FDA's Office of Orphan Drug Products grants orphan status to support drug candidates targeting… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 12, 2021 Category: Biotechnology Authors: John George Source Type: news

Huntsman Cancer Institute researchers identify promising drug combination for melanoma
This study was published in the journalClinical Cancer Research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 3, 2020 Category: Cancer & Oncology Source Type: news

Missing BAP1 gene associated with immunosuppressive molecules in uveal melanoma
(University of Turku) New study from researchers in Finland and the United Kingdom reveals that tumors lacking a protein called BAP1 have an ineffective immune reaction against cancer, thus rendering immunotherapies ineffectual, particularly in uveal melanomas (UM). The researchers also discovered that when BAP1 is lost, other molecules will be present in order to support cancer growth. Luckily, some of these molecules can be targeted with existing drugs, which can lead to the development of novel immunotherapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 9, 2020 Category: Cancer & Oncology Source Type: news

Combination Treatments May Improve Survival for Patients with Metastatic Uveal Melanoma
The authors indicated that prospective clinical trials investigating DTIC-based systemic chemotherapies and liver-directed treatments are necessary to validate their findings. (Source: CancerNetwork)
Source: CancerNetwork - February 6, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news